accountPfizer (NYSE: PFE The company previously announced last November that axitinib had passed its phase 3 trial testing it against Bayer and Onyx Pharmaceuticals' (Nasdaq: ONXX Axitinib extended progression-free survival of...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Pfizer Goes for a One-Two Blockbuster Knockout
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account